Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
1.920
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
November 07, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
November 02, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
August 18, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
June 30, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Business Advisory Board
June 05, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
May 24, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at BIO International Convention 2023
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with First Quarter 2023 Financial Results
May 05, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
April 28, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
April 27, 2023
U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 20, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
April 14, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.